Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 5
Submit an article Journal homepage
130
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

Noam E. Kopmara Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Ted Gooleyb Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Niall Curleya Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Kathryn Russella Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Carole Shawc Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Kelda Schonhoffa Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
John Lima Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Anna B. Halperna Department of Medicine, University of Washington, Seattle, WA, USA;c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Roland B. Waltera Department of Medicine, University of Washington, Seattle, WA, USA;c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA;d Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA;e Department of Epidemiology, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-9268-3341View further author information
ORCID Icon,
Bart L. Scotta Department of Medicine, University of Washington, Seattle, WA, USA;c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Jacob Appelbauma Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Paul C. Hendriea Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Elihu H. Esteya Department of Medicine, University of Washington, Seattle, WA, USA;c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
&
Mary-Elizabeth M. Percivala Department of Medicine, University of Washington, Seattle, WA, USA;c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7016-951XView further author information
ORCID Icon show all
Pages 1057-1059 | Received 04 Jan 2023, Accepted 20 Feb 2023, Published online: 09 Mar 2023

References

  • Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the. Eur J Haematol. 2008;80(2):115–126.
  • Halpern AB, Othus M, Huebner EM, et al. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104(4):e143–e146.
  • Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res. 1970;30(6):1883–1897.
  • Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987;47(11):3005–3011.
  • Garcia-Manero G, Othus M, Pagel JM, et al. SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7 + 3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA + V) in younger patients with previously untreated acute myeloid leukemia (AML). Blood. 2016;128(22):901–901.
  • Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–4423.
  • Godwin CD, Othus M, Powell MA, et al. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2016;57(10):2421–2424.
  • Yuan Y, Hess KR, Hilsenbeck SG, et al. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016;22(17):4291–4301.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.